Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.50 |
| ▸ | ACACB | O00763 | 6/20 | 0.42 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | NTSR1 | P30989 | 3/20 | 0.39 |
| ▸ | KDM1A | O60341 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23019662 | 1.00 | USP30 (0.50) | USP30ACACBDPP4NTSR1KDM1A | |
| SCHEMBL15676534 | 0.88 | ACACB (0.52) | USP30ACACBNTSR1KDM1A | |
| SCHEMBL21259130 | 0.88 | RXRA (0.41) | USP30 | |
| SCHEMBL22289348 | 0.84 | USP30 (0.49) | USP30ACACBNTSR1KDM1A | |
| SCHEMBL22289244 | 0.84 | USP30 (0.49) | USP30ACACBNTSR1KDM1A | |
| SCHEMBL22289245 | 0.84 | USP30 (0.49) | USP30ACACBNTSR1KDM1A | |
| SCHEMBL1911898 | 0.82 | DPP4 (0.51) | USP30ACACBDPP4NTSR1 | |
| SCHEMBL15676531 | 0.81 | ACACB (0.54) | USP30ACACBDPP4 | |
| SCHEMBL1352071 | 0.79 | KHK (0.48) | DPP4KDM1A | |
| SCHEMBL1352068 | 0.79 | KHK (0.48) | DPP4KDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3943490-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2022-01-26 | — | — | EP | disclosed |
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-20 | — | — | US | disclosed |
| EP-3277677-B9 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LTD (GB) | 2021-07-14 | — | — | EP | disclosed |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2021-07-06 | — | — | US | disclosed |
| EP-3842427-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | Mission Therapeutics Limited (GB) | 2021-06-30 | — | — | EP | disclosed |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-23 | — | — | US | disclosed |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-11 | — | — | US | disclosed |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-10-24 | — | — | US | disclosed |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-19 | — | — | US | disclosed |
| US-20190270708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2019-09-05 | — | — | US | disclosed |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | Missions Therapeutics Limited (GB) | 2019-07-09 | — | — | US | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2018-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066365-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | USP30 1/4885ACACB 1553/4885DPP4 1969/4885 |
| US-10343992-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | USP30 1/4885ACACB 2539/4885DPP4 1986/4885 |
| US-11053198-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | USP30 1/4885ACACB 2539/4885DPP4 1986/4885 |
| US-20200181086-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | USP30 1/4885ACACB 2630/4885DPP4 1920/4885 |
| US-20190284138-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | USP30 1/4885ACACB 1553/4885DPP4 1969/4885 |
| US-20180086708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | USP30 1/4885ACACB 2539/4885DPP4 1986/4885 |
| US-20190322624-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | USP30 1/4885ACACB 2539/4885DPP4 1986/4885 |
| US-10689345-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP20, USP10 | USP30 1/4885ACACB 2539/4885DPP4 1986/4885 |
| US-20190270708-A1 | 1-CYANO-PYRROLIDINE COMPOUNDS AS USP30 INHIBITORS | USP30, USP20, USP10 | USP30 1/4885ACACB 2539/4885DPP4 1986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.